Use of eltrombopag in thrombocytopenia of liver disease

Table 2 Studies of Eltrombopag in patients with liver disease

Ref.	Population	Type	Results
McHutchison et al[55]	Compensated HCV cirrhosis with thrombocytopenia	Phase II RCT, placebo controlled	Dose dependent increase noted with eltrombopag
Kawaguchi et al[32]	Cirrhosis	Phase II Randomised Open label study	Risk of thrombotic phenomenon, recommends lower dose in Japanese
Afdhal et al[56] ELEVATE trial	Cirrhosis patients, periprocedural use	Phase III, RCT, placebo controlled	Decreased platelet transfusion with eltrombopag with increased risk of portal vein thrombosis
Afdhal et al[51] ENABLE 1 and 2 trial	HCV related thrombocytopenia, to enable SVR	Phase III, RCT, placebo controlled	Decreased dose reduction in eltrombopag group, Higher SVR

HCV: Hepatitis C virus; SVR: Standard variable rate.